Dreamscape Networks Limited (ASX: DN8)
Dreamscape Networks Limited (ASX: DN8), provides online and cloud-based solutions to customers globally and enables them to find and secure a domain name, web address, initial website design, build and hosting, email, and e-commerce. With a market cap of around $38.88 million and 388.85 million outstanding shares, the DN8 stock closed the day’s trade at $0.135, shooting up 35% on 9th May 2019. DN8’s YTD return is also positive at 23.46%.
On the same day, Dreamscape released its operational and trading update for the second half of 2019 (2HFY19) and the guidance for FY19. Accordingly, total bookings for both the underlying Crazy Domains business (up 9%) and Vodien business (up 19%) continued to perform strongly as compared to the prior corresponding period (pcp) in 2018.
The EBITDA also consistently improved, and cash generation of the company remained robust with the significant restructuring, relocation of the group, as well as the investment in Cebu Infrastructure nearing completion.
Orthocell Limited (ASX: OCC)
Orthocell Limited (ASX: OCC), based in Murdoch, Australia, is a regenerative medicine company that develops cell therapies to repair and regenerate human tendon, bone, etc. The company’s market cap stands at $63.44 million, with around 120.84 million outstanding shares. On 9th May 2019, the OCC stock price settled the day’s trading at $0.415, down 20.952% with ~73.43 million shares traded.
Furthermore, OCC yielded a positive YTD return of 238.71%.
Recently on 8th May 2019, the company reported successful results of CelGro® clinical trial, whereby first four patients completed participation and regained muscle function or sensation of affected limbs and returned to their everyday activities like work, sports etc.
This follows Orthocell’s submission of an application to obtain Therapeutic Goods Administration’s (TGA) approval for introducing CelGro® into the highly prospective Australian commercial market. The company has already received approval for CelGro® in Europe (CE mark). The year-to-date total product revenues for the nine months to 31st March 2019, was up 80% as compared to pcp.
Hannans Limited (ASX: HNR), based in Perth, is engaged in the mineral exploration and project development activities in Australia. It has a bent towards cobalt, gold, nickel, and lithium deposits. The metals and mining sector player’s market cap stands at $27.83 million, with 1.99 billion outstanding shares. On 9th May 2019, the HNR stock price settled the day’s trading at $0.016, zooming up 14.286%, with ~2.99 million shares traded. Moreover, HNR has a positive YTD return of 27.27%.
In its Quarterly Report for the three months to 31st March 2019, Hannans reported that the review of the Forrestania Nickel Project was completed and demonstrated a potential to find another high-grade nickel sulphide deposit, for which the exploration works are underway. Meanwhile, for the Mt Holland Lithium Project, the review of exploration results and strategy was also completed with plans lodged to recommence lithium exploration.
The company’s cash balance as of 31st March 2019, was around $2.86 million, as the operating cash outflows amounted to $282K.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.